For decades, the dominant narrative around Alzheimer’s disease has been one of inevitability — a slow, relentless unraveling with no meaningful way to intervene. Pharmaceutical research has poured billions into amyloid-clearing drugs with discouraging results, and the medical establishment has largely treated Alzheimer’s as a condition to manage rather than prevent or reverse. Into this landscape walks Valter Longo, director of the Longevity Institute at the University of Southern California and one of the world’s leading researchers on aging, nutrition, and the biology of longevity. His work suggests that something as ancient and accessible as fasting may be one of our most powerful tools against neurodegeneration — and the evidence he has assembled is compelling enough to demand serious attention.
The Problem With How We Think About Alzheimer’s
Before understanding what Longo’s research offers, it helps to understand why it matters so much that we have been asking the wrong questions about Alzheimer’s.
The prevailing biomedical model has focused primarily on amyloid-beta plaques and tau tangles — the protein accumulations that characterize Alzheimer’s pathology — as the disease itself. Remove the plaques, the logic goes, and you treat the disease. This approach has produced some of the most expensive clinical trial failures in pharmaceutical history. Drug after drug has successfully cleared amyloid from the brain and failed to improve cognitive outcomes.
A growing number of researchers now argue that amyloid accumulation may be a downstream consequence rather than the root cause — a symptom of metabolic and cellular dysfunction that has been building for decades. Chief among these researchers is Dale Bredesen, who developed the ReCODE protocol, and Valter Longo, whose work on nutrient-sensing pathways and cellular rejuvenation offers a mechanistic framework for why the brain deteriorates in the first place and — crucially — what can be done about it.
Alzheimer’s as a Metabolic Disease
One of the most important reframings in current Alzheimer’s research is the concept of “type 3 diabetes” — a term coined by researcher Suzanne de la Monte to describe the insulin resistance that develops specifically in the brain in Alzheimer’s patients. The Alzheimer’s brain loses its ability to efficiently metabolize glucose, its primary fuel. Neurons that cannot access energy die. The synaptic connections that form memory and cognition deteriorate. In this light, Alzheimer’s is not merely a disease of protein accumulation — it is a disease of impaired cellular energy metabolism.
This is where Longo’s research becomes directly relevant. His decades of work on the IGF-1 signaling pathway, mTOR activity, and nutrient-sensing mechanisms in aging cells provides a coherent biological explanation for how chronic metabolic overactivation contributes to neurodegeneration — and why periodic fasting may interrupt that process.
In healthy individuals, insulin and IGF-1 (insulin-like growth factor 1) signal cells to grow, proliferate, and store energy. When these signals are chronically elevated — as they are in most people eating the standard Western diet — cells remain locked in a pro-growth, pro-inflammatory state. Autophagy, the cellular “self-cleaning” process by which cells break down and recycle damaged proteins and organelles, is suppressed. In the brain, this means that amyloid-beta and hyperphosphorylated tau — the pathological proteins of Alzheimer’s — are not cleared efficiently. They accumulate. The disease progresses.
Fasting suppresses IGF-1 and mTOR signaling. It activates autophagy. It is, in a very real biological sense, the opposite of the metabolic state that drives Alzheimer’s pathology.
The Fasting Mimicking Diet and Alzheimer’s: Animal Evidence
Longo’s most direct contribution to Alzheimer’s research came in a landmark 2019 study published in Cell Reports, in which his laboratory demonstrated the effects of Fasting Mimicking Diet (FMD) cycles on transgenic Alzheimer’s mouse models — animals genetically engineered to develop amyloid plaques, tau tangles, and cognitive decline resembling human Alzheimer’s disease.
The results were striking. Mice subjected to repeated FMD cycles — periods of severe caloric restriction followed by normal refeeding — showed significant reductions in amyloid-beta levels and tau phosphorylation compared to mice fed normally. Neuroinflammation, another hallmark of Alzheimer’s pathology, was also markedly reduced. But perhaps most remarkable were the positive findings: FMD cycles promoted neurogenesis — the growth of new neurons — in the hippocampus, the brain region most critical to memory formation and the first to be devastated by Alzheimer’s. Cognitive performance on standard memory and learning tasks improved significantly.
What the study illuminated was not merely that eating less was neuroprotective. It was that the cyclical nature of the FMD — the rhythm of fasting and refeeding — produced cellular responses that sustained caloric restriction alone does not. The refeeding phase, Longo has argued, is not a break from the therapy. It is part of the therapy. The alternation between metabolic stress and recovery triggers what he calls a regenerative response — a wave of cellular renewal and neurogenesis that occurs in the wake of fasting. This is a crucial distinction that separates the FMD from simple caloric restriction or a ketogenic diet, and it is one that practitioners working with patients in prevention or early intervention contexts need to understand.
The Mechanistic Pathways: Why Fasting Works on the Brain
Longo’s research helps illuminate four distinct mechanisms by which fasting — and the FMD in particular — may protect against or slow Alzheimer’s pathology.
Autophagy activation. When the cell’s nutrient sensors detect a shortage of glucose and amino acids, they initiate autophagy — a process in which cellular “garbage,” including misfolded proteins like amyloid-beta and tau, is tagged, engulfed, and broken down. Chronic overnutrition keeps autophagy suppressed. Fasting switches it back on. In the Alzheimer’s brain, restoring robust autophagy may be one of the most direct ways to reduce the toxic protein burden that kills neurons.
Insulin sensitization and IGF-1 suppression. Fasting dramatically reduces circulating insulin and IGF-1. This matters for the brain in at least two ways. First, reduced insulin resistance at the neuronal level restores the brain’s ability to access glucose — addressing the “type 3 diabetes” energy deficit. Second, lower IGF-1 signaling is associated with reduced tau phosphorylation. Hyperphosphorylated tau is the form that aggregates into neurofibrillary tangles; suppressing the upstream signaling that promotes tau phosphorylation may slow tangle formation at its source.
Ketone production. During fasting, the liver converts fatty acids into ketone bodies — primarily beta-hydroxybutyrate — which the brain can use as an alternative fuel when glucose metabolism is impaired. This is not merely a compensatory mechanism. Ketones are a highly efficient neuronal fuel, and beta-hydroxybutyrate has its own neuroprotective properties, including reduction of oxidative stress and neuroinflammation. For an Alzheimer’s brain struggling to metabolize glucose, the metabolic shift to ketones that fasting induces may represent a literal lifeline for threatened neurons.
BDNF upregulation. Brain-derived neurotrophic factor is perhaps the most important protein for neuronal health and survival. It supports the growth, differentiation, and maintenance of neurons, promotes synaptic plasticity, and has been shown to have antidepressant properties as well. Fasting — along with exercise — is one of the most reliable ways to increase BDNF expression in the brain. In the context of Alzheimer’s, where synaptic loss and neuronal death drive the clinical symptoms, restoring BDNF levels is not a peripheral benefit. It is central to any meaningful neuroprotective strategy.
The Human Picture: Promising but Preliminary
Translating compelling animal data into proven human therapies is always the critical challenge, and Alzheimer’s research has been humbled by this gap before. Longo is a rigorous scientist and does not overclaim. Human trials of the FMD specifically targeting Alzheimer’s biomarkers have been underway, but large-scale completed RCT data in this population remains limited.
What does exist in human research is suggestive. A study from UCLA demonstrated that a 14-hour overnight fast in healthy adults produced measurable reductions in amyloid-beta — a meaningful finding, given that even modest fasting intervals appear to activate the clearance mechanisms Longo’s animal work identified. The broader FINGER trial, conducted in Finland, demonstrated that a multidomain lifestyle intervention — including dietary modification — significantly reduced cognitive decline in at-risk older adults, with effect sizes that drug trials have rarely achieved.
Dale Bredesen’s ReCODE protocol, which incorporates time-restricted eating and ketogenic nutrition as core elements alongside other interventions, has published case series and small trials demonstrating cognitive improvement and even reversal in early Alzheimer’s patients — outcomes previously considered impossible. While this protocol is not Longo’s FMD specifically, it operates through the same fundamental pathways and draws on the same basic science.
One important variable that remains underexplored in human studies is the role of APOE genotype. Carriers of the APOE4 allele — who carry significantly elevated Alzheimer’s risk — may respond differently to dietary fat and fasting interventions, and some researchers have suggested they may require modified protocols. This remains an active area of investigation.
The Cyclical Model: Longo’s Unique Contribution
If there is one idea that distinguishes Longo’s contribution to this field from conventional dietary advice, it is the centrality of the cycle. His FMD is not a permanent dietary restriction. It is a periodic intervention — typically five days of very low calorie, low protein, plant-based nutrition, followed by a return to normal eating. The cycle, repeated monthly or quarterly, is the treatment.
This has profound implications for how we think about both prevention and clinical application. A permanent ketogenic diet, for all its benefits, is difficult to sustain and carries its own metabolic trade-offs. Chronic caloric restriction is psychologically and physiologically demanding. The FMD model offers the benefits of deep fasting — autophagy activation, IGF-1 suppression, ketogenesis, neurogenesis — in a format that is time-limited, repeatable, and increasingly well-characterized in terms of safety.
For prevention in midlife adults, particularly those with family history or APOE4 status, periodic FMD cycles offer a credible biologically-grounded intervention. For clinicians working in integrative or functional medicine contexts, Longo’s framework provides the mechanistic scaffolding to make sense of why patients who fast periodically often report improvements in memory and mental clarity — and to design protocols with more precision.
Conclusion: A Different Way Forward
Valter Longo’s research does not promise a cure for Alzheimer’s. What it offers is something arguably more important: a coherent, mechanistically grounded rationale for why the brain deteriorates under modern metabolic conditions, and a biologically plausible path to interrupting that deterioration. By targeting the nutrient-sensing pathways that drive chronic inflammation, suppressed autophagy, tau phosphorylation, and impaired neuronal energy metabolism, periodic fasting — and the FMD in particular — addresses root causes rather than symptoms.
The animal evidence is strong. The human signals are promising. The biological logic is tight. For anyone working at the intersection of longevity, brain health, and integrative medicine, this is research worth knowing deeply. Alzheimer’s may not be inevitable. And one of our oldest practices — the willful abstention from food — may turn out to be among our most sophisticated tools for fighting it.
Randi Fredricks, Ph.D.
References
Longo VD, Mattson MP. “Fasting: molecular mechanisms and clinical applications.” Cell Metabolism. 2014;19(2):181–192.
Brandhorst S, et al. “A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and healthspan.” Cell Metabolism. 2015;22(1):86–99.
Rangan P, et al. “Fasting-mimicking diet cycles reduce neuroinflammation to attenuate cognitive decline in an Alzheimer’s mouse model.” Cell Reports. 2019;26(13):3713–3728.
Mattson MP, Moehl K, Ghena N, Schmaedick M, Cheng A. “Intermittent metabolic switching, neuroplasticity and brain health.” Nature Reviews Neuroscience. 2018;19(2):81–94.
Bredesen DE. “Reversal of cognitive decline: A novel therapeutic program.” Aging (Albany NY). 2014;6(9):707–717.
de la Monte SM, Wands JR. “Alzheimer’s disease is type 3 diabetes — evidence reviewed.” Journal of Diabetes Science and Technology. 2008;2(6):1101–1113.
Ngandu T, et al. “A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER).” The Lancet. 2015;385(9984):2255–2263.
Longo VD, Panda S. “Fasting, circadian rhythms, and time-restricted feeding in healthy lifespan.” Cell Metabolism. 2016;23(6):1048–1059.
Castellano CA, et al. “A 3-Month Aerobic Training Program Improves Brain Energy Metabolism in Mild Alzheimer’s Disease.” Journal of Alzheimer’s Disease. 2017;56(4):1459–1468.
Neth BJ, et al. “Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebrovascular reactivity in mild cognitive impairment.” Frontiers in Aging Neuroscience. 2020;12:229.
Author Bio
Randi Fredricks, Ph.D. is a leading expert in the field of mental health counseling and psychotherapy, with over three decades of experience in both research and practice. She holds a PhD from The Institute of Transpersonal Psychology and has published ground-breaking research on communication, mental health, and complementary and alternative medicine. Dr. Fredricks is a best-selling author of books on the treatment of mental health conditions with complementary and alternative medicine. Her work has been featured in leading academic journals and is recognized worldwide. She currently is actively involved in developing innovative solutions for treating mental health. To learn more about her work, visit her website: https://drrandifredricks.com
